Registered title, quoted from ClinicalTrials.gov
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Pulmonary Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07410975, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC).
Inclusion criterion 3
No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy. Traditional Chinese medicine given for anticancer intent is permitted provided it was discontinued ≥ 2 weeks before first dose.
Inclusion criterion 4
Major thoracic or abdominal surgery within 28 days before first dose or incomplete recovery from previous surgery.
Exclusion criterion 1
ECOG performance status 0 or 1.
Inclusion criterion 8
Haemoglobin ≥ 90 g/L (no transfusion within 28 days)
Inclusion criterion 10
Absolute neutrophil count ≥ 1.5 × 10⁹/L
Inclusion criterion 11
Platelet count ≥ 100 × 10⁹/L (no platelet transfusion or IL-11 within 14 days)
Inclusion criterion 12
Creatinine clearance ≥ 60 mL/min (Cockcroft-Gault)
Inclusion criterion 13
Total bilirubin ≤ 1.5 × ULN (≤ 2.5 × ULN in Gilbert's syndrome or hepatic metastases)
Inclusion criterion 14
ALT and AST ≤ 3 × ULN
Inclusion criterion 15
INR or aPTT ≤ 1.5 × ULN
Inclusion criterion 16
Active hepatitis B (HBsAg positive and HBV DNA > 500 IU/mL or > 2000 copies/mL) or hepatitis C (HCV antibody and HCV RNA positive). Subjects with HBV DNA ≤ 500 IU/mL who agree to antiviral prophylaxis are eligible.
Exclusion criterion 8
Known HIV infection or history of AIDS.
Exclusion criterion 9
Fertile female must have a negative serum pregnancy test within 7 days before first dose.
Inclusion criterion 18
Fertile female and male patients with female partners of childbearing potential must use a highly effective contraceptive method (annual failure rate < 1 %) from 7 days before first dose until 24 weeks after the last dose.
Inclusion criterion 19
Pregnancy or lactation.
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07410975, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
INCLUSION CRITERIA
- The patient shall sign the informed consent.
- Age ≥ 18 years.
- Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC).
- No prior anticancer therapy, including (but not limited to) chemotherapy, immunotherapy or radiotherapy. Traditional Chinese medicine given for anticancer intent is permitted provided it was discontinued ≥ 2 weeks before first dose.
- Investigator-assessed resectable Stage II-IIIB (N3 excluded) NSCLC per AJCC 9th.
- Non-squamous NSCLC: no EGFR mutation, ALK rearrangement or any other driver mutation with an approved targeted agent. Squamous NSCLC: no known EGFR mutation, ALK rearrangement or other actionable driver mutation.
- PD-L1 expression negative (22C3 or E1L3N).
- ECOG performance status 0 or 1.
- Adequate organ function within 7 days before first dose:
- Haemoglobin ≥ 90 g/L (no transfusion within 28 days)
- Absolute neutrophil count ≥ 1.5 × 10⁹/L
- Platelet count ≥ 100 × 10⁹/L (no platelet transfusion or IL-11 within 14 days)
- Creatinine clearance ≥ 60 mL/min (Cockcroft-Gault)
- Total bilirubin ≤ 1.5 × ULN (≤ 2.5 × ULN in Gilbert's syndrome or hepatic metastases)
- ALT and AST ≤ 3 × ULN
- INR or aPTT ≤ 1.5 × ULN
- FEV> 2L, FEV1> 1L, FEV1/FVC ≥ 70%, DLCO ≥ 70% predicted; or Investigator determination that pulmonary reserve is adequate for planned surgery.
- Fertile female must have a negative serum pregnancy test within 7 days before first dose.
- Fertile female and male patients with female partners of childbearing potential must use a highly effective contraceptive method (annual failure rate < 1 %) from 7 days before first dose until 24 weeks after the last dose.
EXCLUSION CRITERIA
- Major thoracic or abdominal surgery within 28 days before first dose or incomplete recovery from previous surgery.
- Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/day) or other immunosuppressive agents for ≥ 7 consecutive days within 14 days before first dose. Except for inhaled or topical corticosteroids, or corticosteroid therapy at physiological replacement doses for adrenal insufficiency; short- courses (<7 days) corticosteroid use is permitted for the prevention or treatment of non-autoimmune conditions;
- Participants who received live vaccines (including live attenuated vaccines) within 28 days before first dose.
- Current or prior interstitial pneumonia or pulmonary diseases requiring systemic glucocorticoids.
- Presence of any active autoimmune disease or history of autoimmune disease. Except in the following cases: Type 1 diabetes, stable hypothyroidism under hormone replacement therapy, psoriasis or vitiligo not requiring systemic treatment.
- Other malignancy within 5 years before first dose, except for tumors assessed by the investigator as cured.
- Uncontrolled comorbidities, including:
- Active hepatitis B (HBsAg positive and HBV DNA > 500 IU/mL or > 2000 copies/mL) or hepatitis C (HCV antibody and HCV RNA positive). Subjects with HBV DNA ≤ 500 IU/mL who agree to antiviral prophylaxis are eligible.
- Known HIV infection or history of AIDS.
- Active tuberculosis.
- Active infection requiring systemic antibiotics for > 7 days within 28 days before first dose.
- Clinically significant cardiovascular disease: cerebrovascular accident within 6 months, symptomatic heart failure (NYHA class II-IV), unstable angina or myocardial infarction within 6 months, risk of QTc prolongation or arrhythmia.
- Urine protein qualitative≥ 2+, and 24-hour urine protein test > 1g
- History of allogeneic haematopoietic stem-cell or solid-organ transplantation.
- Hypersensitivity to antibody therapies (≥ grade 3 NCI-CTCAE v6.0), history of anaphylaxis, uncontrolled asthma, or significant drug allergies.
- Pregnancy or lactation.
- Other conditions that may affect the safety or compliance of drug therapy in this study include, but are not limited to, psychiatric disorders, uncontrolled large serosal cavity effusions, or moderate to large serosal cavity effusions requiring repeated drainage (recurring within 2 weeks after intervention), such as pleural effusion, pericardial effusion, or ascites cachexia.
Quoted from ClinicalTrials.gov, NCT07410975, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07410975, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.